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Purpose: The effects of maternal systemic lupus erythe-
matosus (SLE) on neonatal prognosis were examined by
comparing clinical features of full-term babies born to lupus
mothers and age- and parity-matched controls. Patients and
Methods: From January 2000 to December 2005, 39 singletons
were born to 37 SLE women. Excluding 11 cases of
prematurity and preeclampsia, 28 full-term neonates formed
the lupus group. The control group included 66 full-term
babies. The retrospective study examined medical records and
compared gestational age, birth weight, days of hospital stay,
small for gestational age (SGA) frequency, Apgar scores < 7,
and parity. Lupus neonates were tested for anti-nuclear
antibody (ANA) and platelet count, and electrocardiogram was
performed. Results: Average gestational age (38 vs. 39 weeks,
p < 0.05) and birth weight (2,775 vs. 3,263 g, p < 0.05) were
significantly different between the SLE and control groups.
SGA frequency was higher in the SLE group (25% vs. 4.5%,
p < 0.05). No significant difference was observed in Apgar
score, birth weight, gestational age, SGA frequency, and
platelet count between lupus subgroups formed based on
anti-dsDNA antibody levels and antiphospholipid antibody
status. Conclusion: The association of maternal ANAs,
antiphospholipid antibodies, and drug history with neonatal
prognosis could not be elucidated. However, even in
uncomplicated pregnancies, maternal lupus is disadvantageous
for gestational age, birth weight, and SGA frequency.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is an
important risk factor for mothers during pregnancy
and the puerperal period. Lupus women are
thought to experience disease deterioration due to
pregnancy, but varying incidence rates have been
reported.
1 Maternal lupus is known to influence
fetal and neonatal outcomes and is associated
with increased incidence of obstetric complications
such as stillbirth, abortion, prematurity, intrauterine
growth restriction (IUGR), and neonatal com-
plications such as congenital heart block and
neonatal lupus.
1-3 In particular, mothers with
increased SLE activity, lupus nephritis, hyperten-
sion, and who are positive for antiphospholipid
and anti-Ro/ SS-A antibodies have relatively poor
fetal and neonatal prognosis. However, few
studies have investigated the neonatal prognosis
in SLE mothers who delivered at full term
without obstetrical complications.
1
Our study focused on the effects of SLE on
perinatal outcome by comparing clinical features
of full-term neonates born to lupus mothers and
normal pregnant women.
PATIENTS AND METHODS
Patients
From January 2000 to December 2005, 37
pregnant women with lupus gave birth at the
Kangnam St. Mary's Hospital, The Catholic
University of Korea, and 2 women gave birth
twice. These women were diagnosed with SLE at
the Department of Internal Medicine of the same
hospital, and the average duration between
diagnosis and delivery was 6.2 years. Of the 39
neonates, 8 born prematurely and 3 born to
preeclamptic mothers were excluded, and 28
full-term neonates born between 37 and 41 weeks
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of gestation were included in the lupus group.
The control group included 66 full-term neonates
born to age- and parity-matched pregnant women.
The distribution of pregnant women in the 2
groups was 27 in the lupus group and 66 in the
control group. We excluded women with
conditions that could influence perinatal prognosis
such as premature rupture of membranes (PROM),
placental abruption, placenta previa, gestational
diabetes, chronic or pregnancy hypertension, and
chromosomal abnormalities.
Methods
This retrospective study investigated medical
records of subjects. The lupus and control groups
were compared with respect to gestational age,
birth weight, days of hospital stay, SGA, Apgar
score, and parity. In the lupus group, ANA titers
and platelet count were assessed at birth, and
electrocardiogram monitoring was performed
until discharge. ANA-positive neonates were
followed p until conversion to negative was
confirmed.
On the other hand, based on the maternal ANA
titers prior to delivery, the lupus group was
divided into 2 sets of subgroups: (i) cases with
anti-dsDNA antibody values greater than 100
IU/mL (10 neonates) and cases with values lower
than 100 IU/mL (18) and (ii) cases positive for
antiphospholipid autoantibody (6) or negative
cases (22). The respective subgroups were
compared with respect to 1-min and 5-min Apgar
scores less than 7, birth weight, gestational age,
SGA frequency, and platelet count.
Antiphospholipid antibody-positive cases were
defined as those that were positive for any of the
following: anticardiolipin antibody, lupus anticoa-
gulant, or VDRL (the positive VDRL result was a
false positive).
Statistical analysis
SPSS for Windows (ver. 12.0) was used for
statistical analysis, Mann-Whitney test for con-
tinuous variables, and Fisher's exact test for non-
continuous variables.
RESULTS
Comparison of maternal demographic data
The mean age of the pregnant women was 31.9
years in the control group and 30.5 years in the
lupus group. Among 27 pregnant women of the
lupus group (28 neonates), 17 were primiparas
and 10 were multiparas. In the control group (66
neonates), 32 women were primiparas and 34 were
multiparas. There were no significant differences
in age of mothers and ratio of primiparas to
multiparas between the 2 groups (Table 1).
Regarding the parity of the mothers, there were
12 abortions (48%) and 4 prematurities (16%)
among the 25 pregnancies in the lupus group.
Among the 75 pregnancies in the control group,
there were 32 abortions (42.6%) and 3 prema-
turities (4%). The incidence of abortion and
prematurity was not statistically significantly
different between the 2 groups (Table 1).
Table 1. Comparison of Perinatal History between Lupus and Control Groups
   Lupus mothers
(n = 27)
Control mothers
(n = 66)
p value
Age* (yrs) 30.5 ± 2.9 31.9 ± 3.9 0.08
Primipara to multipara ratio 17 : 10 32 : 34 0.25
§
Abortion history 12 32 0.63
Prematurity history 4 3 0.12
*Mean ± SD.
Number.
vs. controls by Mann-Whitney test.
§vs. controls by Fisher's exact test.Prognosis of Neonates in Lupus Mothers
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Comparison of perinatal outcome between SLE
and control groups
The gender ratio of neonates was 1 : 1.8 in the
lupus group (10 males and 18 females) and 1 : 1
in the control group. The average gestational age
and birth weight were 38 weeks and 4 days and
2,775 g in the lupus group (28 neonates) and 39
weeks and 5 days and 3,263 g in the control group
(66 neonates), respectively, and a significant
difference was observed between the 2 groups (p
< 0.05). The frequency of SGA was 7 cases (25%)
in the lupus group and 3 (4.5%) in the control
group, and a significant difference was observed
between the 2 groups (p < 0.05). Thus, compared
with the control group, the lupus group had
relatively lower birth weight and gestational age
and higher SGA frequency (Table 2). There were
no significant differences in gender ratio, 1-min
and 5-min Apgar scores < 7, and days of hospital
stay between the 2 groups.
Antinuclear antibody and platelet count of neonates
ANA testing was performed in 17 neonates in
the lupus group; 10 neonates were tested positive
for anti-dsDNA antibodies at birth and converted
to negative at 6 - 12 month after birth. Anti-Ro/
SS-A and anti-La/SS-B antibodies were detected
in 5 and 3 neonates, respectively (Table 3). Three
cases were tested positive for Ro/SS-A and
La/SS-B autoantibodies in concomitance.
None of the neonates showed congenital heart
block on electrocardiogram at birth and during
Table 2. Comparison of Perinatal Outcomes between Lupus and Control Groups
 
Lupus
(28 neonates)
Control
(66 neonates)
p value
Gender (M : F) 1 : 1.8 1 : 1 0.260
§
Birth weight (g)* 2,775 ± 360 3,263 ± 404 0.000
Gestational age (wks)* 38.4 ± 1.0 39.5 ± 0.9 0.000
Hospital stay (d)* 3.57 ± 3.0 2.83 ± 1.8 0.461
Small for gestational age 7 (25%) 3 (4.5%) 0.007
§
Apgar score < 7 (1 min) 2 (7.1%) 1 (1.5%) 0.211
§
Apgar score < 7 (5 min) 1 (3.5%) 0 (0%) 0.298
§
*Mean ± SD.
Number (%).
vs. controls by Mann-Whitney test.
§vs. controls by Fisher's exact test.
Table 3. Laboratory Findings of Lupus Group
  Lupus group (28 neonates)
Platelet (/mm
3)* 219,820 ± 63,835
Anti-dsDNA antibody (positive) 10 (35.7%)
Anti-Ro/SS-A antibody (positive) 5 (17.9%)
Anti-La/SS-B antibody (positive) 3 (10.7%)
Anti-dsDNA antibody titer (mother) > 100 IU/mL 10 (35.7%)
< 100 IU/mL 18 (64.3%)
Antiphospholipid antibody (mother, positive ) 6 (21.4%)
*Mean ± SD.
Number (%).
Lupus anticoagulant (+), anticardiolipin antibody (+), or VDRL (+; the positive VDRL result was a false positive).So-Young Kim and Jung-Hyun Lee
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the monitoring period or developed neonatal
lupus due to ANA transmission from the mother.
Among the pregnant women in the lupus
group, thrombocytopenia (platelet count of
mother < 100,000/mm
3) was observed in 7 women
(25.9%) and 2 of their neonates (platelet count of
neonate < 150,000/mm
3). In all, 5 neonates showed
thrombocytopenia (platelet count of neonate <
150,000/mm
3), and they recovered within 14 days
after birth without any special treatment.
Perinatal outcome according to lupus activity
The 2 lupus subgroups based on the maternal
anti-dsDNA antibody titers showed no significant
differences in 1-minute and 5-minute Apgar scores
< 7, birth weight, gestational age, SGA frequency,
and platelet count (Table 4). The differences in the
clinical manifestations including a history of
thrombosis, late-term pregnancy loss, or 3 prior
first-trimester miscarriages observed between the
2 subgroups was not significant.
Similarly, the 2 lupus subgroups, based on
antiphospholipid autoantibody status, showed no
significant differences in 1-minute and 5-minute
Apgar scores of the neonates, birth weight,
gestational age, SGA frequency, and platelet count
(Table 5). Meanwhile, patients with or without
antiphospholipidic antibodies (aPL) were provided
with similar treatment. In the lupus group, medi-
cation history prior to pregnancy included systemic
steroids in 25 patients, hydroxychloroquine in 11,
Table 4. Comparison of Perinatal Outcomes between High- and Low-risk Subgroups (by anti-dsDNA antibody
titer) in Lupus Group
  100 IU/mL
(10 neonates)
< 100 IU/mL
(18 neonates) p value
Birth weight (g)* 2,641 ± 367  2,850 ± 344 0.2
Gestational age (wks)* 38.2 ± 0.9  38.5 ± 1.1  0.4
Platelets (/mm
3)* 229,000 ± 60,046 218,940 ± 66,836 1.0
Small for gestational age 3 (30.0%) 4 (22.2%) 0.6
§
Apgar score < 7 (1 min) 0 (0.0%) 2 (11.1%) 0.5
§
Apgar score < 7 (5 min) 0 (0.0%) 1 (5.6%) 1.0
§
*Mean ± SD.
Number (%).
vs. controls by Mann-Whitney test.
§vs. controls by Fisher's exact test.
Table 5. Comparison of Perinatal Outcomes between aPL-positive and -negative Subgroups in Lupus Group
 
 Positive
(6 neonates)
Negative
(22 neonates)
p value
Birth weight (g)* 2,866 ± 158 2,750 ± 397 0.3
Gestational age (wks)* 38.8 ± 0.75 38.3 ± 1.1 0.2
Platelets (/mm
3)* 263,170 ± 45,446 210,620 ± 64,101 0.1
Small for gestational age 0 (0.0%) 7 (31.8%) 0.2
§
Apgar score < 7 (1 min) 0 (0.0%) 2 (9.1%) 1.0
§
Apgar score < 7 (5 min) 0 (0.0%) 1 (4.5%) 1.0
§
*Mean ± SD.
Number (%).
vs. controls by Mann-Whitney test.
§vs. controls by Fisher's exact test.Prognosis of Neonates in Lupus Mothers
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azathioprine in 2, methotrexate in 1 (the neonate
did not exhibit any fetal abnormality), and aspirin
in 10. In 6 patients with aPL, medication history
prior to pregnancy included systemic steroids in
6 patients, hydroxychloroquine in 3, azathioprine
in 2, and aspirin in 4. Furthermore, medication
history of patients with aPL during pregnancy
included systemic steroids in 6 patients and
aspirin in 4.
DISCUSSION
Lupus mothers have a high risk of experiencing
spontaneous abortion, stillbirth, prematurity, and
IUGR.
1-4 In 1993, Petri et al.
5 examined 481
neonates born to 203 lupus women and the
incidence of spontaneous abortion and stillbirth
was 21% and prematurity was 12%. These
incidence rates were significantly higher than those
in healthy pregnant women. In 2000, Georgiou et
al.
6 reported that, among the 59 neonates born to
47 lupus mothers, 5% were born prematurely. In
our study, 37 lupus women delivered 39 neonates
of which 8 (20.5%) were born prematurely. This
is a very high rate when compared with the
prematurity rate of 0.9% (9 in 1,000 deliveries)
reported by the Korea National Statistical Office
in 2005. Regarding the parity of the lupus group
(28 neonates), there were 12 abortions (48%) and
4 premature deliveries (16%) among a total of 25
pregnancies, whereas there were 32 abortions
(42.6%) and 3 premature deliveries (4%) among a
total of 75 pregnancies in the control group. Thus,
the frequency of prematurity and abortion was
higher in the lupus group than the control group,
however, a statistically significant difference was
not observed. In another Korean report
7 investiga-
ting the parity of 91 lupus women from 1990 to
1996, the fetal loss was 19.7% and prematurity
rate was 35.6%. The rates observed in the present
study were lower, which might be due to the in-
clusion of lupus mothers with full-term deliveries.
Poor neonatal prognosis has been reported in
lupus women with disease deterioration, ANA-
positive status, or increased ANA titers.
8,9
However, in our study, a significant difference in
neonatal prognosis was not observed between the
2 lupus subgroups based on anti-dsDNA antibody
titers 100 and < 100. This could due to the fact
that subjects were restricted to healthy full-term
neonates born to mothers without preeclampsia.
The presence of aPL in lupus mothers is 30 - 40%,
2
and this is associated with frequent abortion,
IUGR, oligohydramnios, preeclampsia, stillbirth,
and HELLP syndrome.
1-4,10 In 2003, Moroni et al.
11
reported a strong possibility of lupus mothers
positive for aPL or with nephritis losing their
fetuses due to factors such as stillbirth and
abortion, and the incidence of abortion varied
from 30% to 83%. In comparison, in lupus
mothers without aPL, the incidence of abortion
was 4 - 43%, which was lower than that in
mothers positive for these antibodies. However, it
has been reported that chances of stillbirth or
abortion in mothers positive for aPL could be
reduced by aspirin or heparin treatment.10 In our
study, among the 28 neonates, maternal aPL were
detected in 6 cases (21.4%) and there were only 2
abortions (33.3%). In 22 mothers negative for aPL,
10 (45.4%) had a history of abortion. Thus, our
results differ from those reported by Moroni in
2003.11 In addition, a comparison of pregnant
women testing positive (6 neonates) and negative
(22 neonates) for aPL showed no differences in
Apgar scores of neonates, birth weight, gestational
age, SGA frequency, and platelet count. However,
it appears to be necessary to conduct additional
studies with a larger number of subjects.
It has been reported that besides aPL, the
presence of ANAs during pregnancy may affect
the prognosis of the perinatal period.
12 In parti-
cular, anti-Ro/SS-A and anti-La/SS-B antibodies
were associated with neonatal lupus
2 and congenital
heart block, but, they were not associated with
stillbirth, abortion, and prematurity.
13
Many lupus mothers take medications during
pregnancy. Steroids are relatively safe in pregnant
women,
2 and it has been reported that fetal
mortality and morbidity rates decreased in lupus
mothers when treated with steroids.
14 However,
Molad et al.
1 have reported in 2005 that not only
high lupus activity but also hypoalbuminemia,
proteinuria, presence of ANAs, and history of
drugs such as steroids and hydroxychloroquine
could be risk factors in lupus mothers. In our
study, 25 among the 27 lupus women (92.6%) had
received systemic steroid treatment, but, it couldSo-Young Kim and Jung-Hyun Lee
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not be determined whether this acted as an
advantageous factor in maintaining the pregnancy
to full term.
In our study, 5 among the 28 lupus neonates
showed thrombocytopenia with platelet counts in
the range of 83,000 to 149,000/mm
3. Platelet count
became normal within 2 weeks in most cases, and
administration of immunoglobulin or other drugs
was not required. Our findings were different
from those of other reports
15 in that the problem
of thrombocytopenia was not greatly enhanced.
This is thought to be due to the inclusion of full-
term neonates and low-risk pregnancy subjects
without complications such as preeclampsia and
prematurity.
In a Korean study on 11 neonates born to 9 SLE
women, 9 women had a total of 30 pregnancies
among which there were 6 spontaneous abortions
(20.0%) and 5 stillbirths (16.7%), and among the
neonates, 4 were born prematurely (36.4%) and 2
were SGA (19.2%).
15 From birth, 2 neonates showed
thrombocytopenia and leucopenia, and 2 pregnant
women positive for lupus anticoagulant and aPL
experienced preterm delivery.
15
Thus, obstetrical complications may develop in
lupus women in whom pregnancy is maintained,
and their prognosis has been reported to be poor.
However, few studies have examined the neonatal
prognosis in lupus women who delivered at full
term.
In 2005, Coleman et al.
12 reported that, at birth,
a statistical difference was not observed in the
weight and height of 23 neonates born to lupus
women and 115 neonates born to healthy mothers.
The explanation provided for this result was that
the number of subjects in the lupus group was
small, and factors influencing the prognosis of
pregnant women such as nutrition, parity, and
maternal comorbidity were not assessed. However,
in our study, a comparison of the lupus group, in
which pregnancy was maintained to full term by
administering prenatal care for diverse obstetrical
complications with the control group showed that
birth weight and gestational age of the lupus
group were lower and incidence of SGA was
higher.
The perinatal prognosis of lupus mothers is
poor in comparison with normal pregnant
women. Therefore, even if the pregnancy could be
maintained until full term by avoiding obstetrical
complications that might develop during pre-
gnancy and delivery, cautious evaluation and
treatment of the neonates are essential.
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